134190-11-7

Basic information

• Product Name: (D-HIS(BZL)6,PRO-NHET9)-LHRH (2-9)
• Synonyms: H-HIS-TRP-SER-TYR-D-HIS(BZL)-LEU-ARG-PRO-NHET;(D-HIS(BZL)6,PRO-NHET9)-GONADOTROPIN-RELEASING HORMONE (2-9);(D-HIS(BZL)6,PRO-NHET9)-LHRH (2-9);(D-HIS(BZL)6,PRO-NHET9)-LUTEINIZING HORMONE-RELEASING FACTOR (2-9);(D-HIS(BZL)6,PRO-NHET9)-LUTEINIZING HORMONE-RELEASING HORMONE (2-9);(Des-Pyr1)-Histrelin, (Des-Pyr1,Des-Gly10,D-His(Bzl)6,Pro-NHEt9)-LHRH
• CAS NO: 134190-11-7
• Molecular Formula: C₆₁H₈₁N₁₇O₁₀
• Molecular Weight: 1212.4
• Mol File: 134190-11-7.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.42±0.1 g/cm3(Predicted)
• Storage Temp.: -15°C
• PKA: 9.82±0.15(Predicted)
• CAS DataBase Reference: (D-HIS(BZL)6,PRO-NHET9)-LHRH (2-9)(CAS DataBase Reference)
• NIST Chemistry Reference: (D-HIS(BZL)6,PRO-NHET9)-LHRH (2-9)(134190-11-7)
• EPA Substance Registry System: (D-HIS(BZL)6,PRO-NHET9)-LHRH (2-9)(134190-11-7)

Safety Data

• Hazardous Substances Data: 134190-11-7(Hazardous Substances Data)

Usage

Description

(D-HIS(BZL)6,PRO-NHET9)-LHRH (2-9) is a synthetic peptide hormone that functions as a modified version of luteinizing hormone-releasing hormone (LHRH). This peptide has been specifically engineered to increase its stability and potency, with the inclusion of a D-HIS(BZL)6 residue, a variant of the histidine amino acid, and a PRO-NHET9 residue, a variant of proline. These alterations enhance the peptide's binding affinity and biological activity, making it a candidate for treating hormone-dependent conditions.

Uses

Used in Pharmaceutical Industry:
(D-HIS(BZL)6,PRO-NHET9)-LHRH (2-9) is used as a therapeutic agent for the treatment of hormone-dependent cancers, such as prostate and breast cancer. Its application is based on its ability to mimic the activity of LHRH, which plays a crucial role in regulating the body's hormonal balance. By targeting and disrupting the hormonal pathways that fuel the growth of certain cancers, this synthetic peptide hormone can potentially inhibit tumor growth and progression.
Additionally, due to its enhanced stability and potency, (D-HIS(BZL)6,PRO-NHET9)-LHRH (2-9) may also be utilized in the development of drug delivery systems to improve the efficacy and bioavailability of other cancer treatments, similar to the application of gallotannin in drug delivery systems.

Upstream product

• 76712-82-8 histrelin 

Relevant articles and documents

Characterization of the solution degradation products of histrelin, a gonadotropin releasing hormone (LH/RH) agonist

The degradation products of histrelin (1, Glu-His-Trp-Ser-Tyr-(D-N(im)-bzl-His)-Leu-Arg-Pro-NHEt) were determined in aqueous solution at pH 5.4 and 87°C over an 18-day period (47% degradation). These degradation products (2-5) resulted from the cleavage of Glu-His and Trp-Ser peptide bonds, His-Trp diketopiperazine formation, and racemization of serine and histidine residues.